EGFR and non-small cell lung carcinoma: Accordingly, our results suggested that the recycling endosome route was more prominent in response to the gefitinib treatment in the NSCLC cells harboring primary EGFR mutation, which will promote the TKI therapeutic efficacy and cell death.